ClinicalTrials.gg
TerminatedNCT00662740Updated Oct 29, 2026Results posted

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of FDC tiotropium / salmeterol and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Terminated at 72 sites in 18 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Updated Oct 29, 2026Results postedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Boehringer Ingelheim.

Enrollment
66th of 155
220 · median 166
Started
2008
with 10 others
Phase 3
81 of 236
1 open now
Registered
59th of 236
by date

Among the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, this one is the 66th largest by enrollment of the 155 interventional ones that give a count, is one of 11 that started in 2008, is one of 81 in phase 3, and was the 59th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Disease, Chronic Obstructive by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main:

  • Diagnosis of (COPD)
  • Post-bronchodilator (FEV1) \<80% predicted and FEV1/forced vital capacity (FVC) \<70% predicted

Exclusion criteria

Exclusion criteria:

Main:

  • Significant other diseases then
  • Recent myocardial infarction (MI)
  • Any unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year
  • Hospitalisation for cardiac failure during the past year
  • History of asthma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    FDC tiotropium / salmeterol (T+S_PE)

    One fixed dose combination (FDC) capsule of inhalation powder containing 7.5 micrograms Tiotropium and 25 micrograms of salmeterol were administered orally once daily in the morning from blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered twice daily in the morning from the grey HandiHaler® device, and in the evening from blue HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.

    Drug: FDC tiotropium / salmeterol

  • Active comparator
    tiotropium (Tio18GEL)

    One dose gelatine capsule of inhalation powder containing 18 micrograms tiotropium was administered orally once daily in the morning from the grey HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered twice daily in the morning and evening from the blue HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.

    Drug: Tiotropium (Spiriva®)

  • Active comparator
    salmeterol (Salm25PE)

    One dose polyethylene capsule of inhalation powder containing 25 micrograms salmeterol was administered orally twice daily in the morning and evening from the blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered once daily in the morning from the grey HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.

    Drug: Salmeterol

  • Active comparator
    FDC tiotropium / salmeterol + salmeterol (T+S_PE / S25PE)

    One fixed dose combination (FDC) capsule of inhalation powder containing 7.5 micrograms tiotropium and 25 micrograms salmeterol was administered orally once daily in the morning from the blue HandiHaler® device and one dose of inhalation powder containing 25 micrograms salmeterol was administered once daily in the evening from the blue HandiHaler® device for treatment duration of 24 weeks (+24 week extension). One capsule of inhalation powder of placebo was administered once daily in the morning from the grey HandiHaler® device. The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.

    Drug: FDC tiotropium / salmeterol · Drug: Salmeterol

  • Placebo comparator
    Placebo

    One capsule of inhalation powder of placebo was administered daily in the morning from the blue and grey HandiHaler® device and in the evening from the blue HandiHaler® device for treatment duration of 12 weeks (Patients randomized into the placebo group will be re-assigned at random to one of the four active treatments (T+S\_PE, Tio18GEL, Salm25PE, T+S\_PE/S25PE) for the remaining 36 weeks of the 48-week study period.). The morning and evening dose of study medication had to be taken at approximately the same time, the evening dose had to be taken approximately 12 hours after the morning dose. All medications were self-administered by patients.

    Drug: Placebo

Interventions

  • DrugFDC tiotropium / salmeterol

    Fixed-dose combination Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene (PE) Capsule

  • DrugPlacebo

    Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule

  • DrugSalmeterol XinafoateStudies of Salmeterol XinafoateSalmeterol Xinafoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Salmeterol Inhalation Powder, hard PE capsule

  • DrugTiotropiumStudies of TiotropiumTiotropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tiotropium, Spiriva®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period

    Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)

    Time frame: At baseline and week 12

  2. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

    Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 min time point just prior to inhalation of the morning dose of randomised treatment.

    Time frame: At baseline and week 24

  3. Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period

    Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 12 - trough FEV1 at baseline.

    Time frame: At baseline and at week 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  4. Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 24-week Treatment Period

    Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 24 - trough FEV1 at baseline.

    Time frame: At baseline and at week 24: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  5. Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

    Time frame: At the end of week 12

  6. Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 24-week Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

    Time frame: At the end of week 24

  7. St George Respiratory Questionnaire (SGRQ) Total Score at the End of the 24-week Treatment Period (Based Upon Pooled Data From 48-week Sister Studies 1184.14 and 1184.15)

    The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. The evaluation SGRQ was planned to be based upon pooled data from 48-week sister studies 1184.14 and 1184.15.

    Time frame: At the end of week 24

  8. Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks

    Time from start of treatment to first moderate to severe chronic obstructive pulmonary disease (COPD) exacerbation within 48 weeks is presented.

    Time frame: Up to 12 weeks

  9. Number of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 Weeks

    Number of patients with moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations within 48 weeks is presented.

    Time frame: Up to 12 weeks.

Secondary outcomes

  1. Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period

    Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 4, 36 or 48 - trough FEV1 at baseline.

    Time frame: At baseline and at week 4: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  2. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period

    Change from baseline in trough Forced Expiratory Volume in one second (FEV1) after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)

    Time frame: At baseline and week 4

  3. Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Peak FEV1 is defined as the highest FEV1 reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FEV1 response is defined as the change from baseline: Peak FEV1 response = Peak FEV1 - FEV1 (Baseline)

    Time frame: At baseline and at week 4 and 12: within 3h after inhalation of the morning dose of randomised treatment.

  4. The Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment Period

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC AUC0-8h is defined as the area under the FVC curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FVC was assigned to zero time. Trough FVC at baseline is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FVC AUC0-8h at week 4, 12, 24, 36 or 48 - trough FVC at baseline.

    Time frame: At baseline and at week 4 and 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  5. Change From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment Period

    Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FVC response is defined as the change from baseline: Trough FVC response = Trough FVC - FVC (Baseline)

    Time frame: At baseline and week 4 and 12

  6. Change From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48

    Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC is defined as the highest FVC reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FVC response is defined as the change from baseline: Peak FVC response = Peak FVC - FVC (Baseline)

    Time frame: At baseline and at week 4 and 12: within 3 hours after inhalation of the morning dose of randomised treatment.

  7. Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4

    Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 4 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.

    Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  8. Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12

    Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 12 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.

    Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  9. Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4

    Forced Vital Capacity (FVC) at clinic visits at the individual times on week 4 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.

    Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  10. Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12

    Forced Vital Capacity (FVC) at clinic visits at the individual times on week 12 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.

    Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  11. Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4

    Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 4 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

    Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  12. Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12

    Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 12 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

    Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

  13. Weekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)

    Weekly mean morning pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their morning study medications prior to each morning PEF measurement.

    Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.

  14. Weekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)

    Weekly mean evening pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their evening study medications prior to each evening PEF measurement.

    Time frame: At week 1 to 14, each evening between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.

  15. Peak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48

    Peak expiratory flow (PEF) are determined by spirometry at clinic visits (week 4, 12, 18, 24, 36 and 48) is presented. Spirometry will begin between 07:00 and 10:00 a.m. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

    Time frame: At week 4 and 12: 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment.

  16. Weekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)

    Weekly mean morning pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their morning study medications prior to each morning FEV1 measurement.

    Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.

  17. Weekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)

    Weekly mean evening pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their evening study medications prior to each evening FEV1 measurement.

    Time frame: At week 1 to 14, each morning between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.

  18. Weekly Mean Number Per Day of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

    Weekly mean number per day of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

    Time frame: Weekly up to week 14: per day (24 hours period)

  19. Weekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

    Weekly mean number at daytime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

    Time frame: Weekly up to week 14: at daytime (from morning dose till evening dose of study medication)

  20. Weekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

    Weekly mean number at nighttime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

    Time frame: Weekly up to week 14: at nighttime (from evening dose till morning dose of study medication)

  21. Weekly Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Nighttime Awakenings

    Weekly mean number of chronic obstructive pulmonary disease (COPD)-related nighttime awakenings is presented.

    Time frame: Per week, up to 14 weeks

  22. Mahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major detonation) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

    Time frame: At week 4

  23. Mahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - functional impairment is based on the criteria of change in functional impairment (any activities started or stopped?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

    Time frame: At the end of week 4 and 12.

  24. Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of task is based on the criteria of change in magnitude of task (What activities cause breathlessness now?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

    Time frame: At the end of week 4 and 12.

  25. Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

    The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of effort is based on the criteria of change in magnitude of effort (Need to pause while performing activities?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

    Time frame: At the end of week 4 and 12.

  26. St George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 Weeks

    The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At week 4 and 12.

  27. St George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 Weeks

    The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The impact domain score is a part of the SGRQ that measures the impact of disease on daily life. Its scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At week 4 and 12.

  28. St George Respiratory Questionnaire (SGRQ) Activity Domain Score Collected at 4, 12, 36 and 48 Weeks

    The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The activity domain score is a part of the SGRQ that measures the activity of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At week 4 and 12.

  29. St George Respiratory Questionnaire (SGRQ) Symptoms Domain Score Collected at 4, 12, 36 and 48 Weeks

    The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The symptoms domain score is a part of the SGRQ that measures the symptoms of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: At week 4 and 12.

  30. Number of Patients With Adverse Events Within the 48-week Treatment Period

    Number of patients with adverse events within the 48-week treatment period is presented. A patient may be counted in more than one seriousness criterion.

    Time frame: From randomisation till end of treatment, up to 12 weeks.

  31. Number of Patients With Marked Changes in Vital Signs (Decrease) by Clinic Visit

    Number of patients with marked changes in vital signs (decrease) by clinic visit is presented. Vital signs: pulse rate and blood pressure (BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Decrease: Below 100 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Diastolic BP Decrease: Below 60 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Pulse rate Decrease: Below 60 bpm if not at that level at baseline and a decrease of greater than 10 bpm below baseline.

    Time frame: At baseline, week 4 and week 12.

  32. Number of Patients With Marked Changes in Vital Signs (Increase) by Clinic Visit

    Number of patients with marked changes in vital signs (increase) by clinic visit is presented. Vital signs: pulse rate and blood pressure 8BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Increase : An increase of 25 mmHg or more above baseline. Diastolic BP Increase: Above 90 mmHg at baseline and an increase of greater than 10 mmHg above baseline. Pulse rate Increase : Greater than 100 bpm if not at that level at baseline and an increase greater than 10 above baseline.

    Time frame: At baseline, week 4 and week 12.

  33. Number of Patients With Abnormal Haematology at the End of the 12-week Treatment Period

    Number of patients with abnormal haematology at the end of the 12-week treatment period is presented.

    Time frame: At the end of the 12-week treatment period.

  34. Number of Patients With Abnormal Blood Chemistry at the End of the 12-week Treatment Period

    Number of patients with abnormal blood chemistry at the end of the 12-week treatment period is presented.

    Time frame: At the end of the 12-week treatment period.

  35. Number of Patients With Abnormal Urinalysis at the End of the 12-week Treatment Period

    Number of patients with abnormal urinalysis at the end of the 12-week treatment period is presented.

    Time frame: At the end of the 12-week treatment period.

  36. Vital Status of Randomised Patients

    Vital status of randomised patients is presented.

    Time frame: Up to 48 weeks.

  37. Number of Days in Hospital Within the 48-week Treatment Period

    Number of days in hospital within the 48-week treatment period is presented.

    Time frame: Up to 12 weeks.

  38. Number of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period

    Number of unscheduled health care provider visits within the 48-week treatment period is presented.

    Time frame: Up to 12 weeks.

  39. Number of Emergency Room Visits Within the 48-week Treatment Period

    Number of emergency room visits within the 48-week treatment period is presented.

    Time frame: Up to 12 weeks.

  40. Number of Days in Intensive Care Unit Within the 48-week Treatment Period

    Number of days in intensive care unit within the 48-week treatment period is presented.

    Time frame: Up to 12 weeks.

  41. Number of Patients Receiving Concomitant Medication

    Number of patients receiving concomitant medication is presented. Concomitant medication was observed for rerandomized placebo patients during placebo treatment and on-treatment periods.

    Time frame: Up to 12 weeks.

07

Results

Posted Oct 29, 2026
Limitations and caveats
The company decision to discontinue 1184.14 was for strategic reasons and not based on any safety or efficacy decision. The decision to terminate the 48-week trial 1184.14 was made shortly after study start, meaning that not only a limited number of patients had been randomised to study drug but also that only a few patients had completed the first 12-week treatment period and, therefore, the originally planned statistical analysis for all endpoints were not performed due to lack of data.

Participant flow

24-week (+ 24 week extension) placebo-controlled (only 1st 12-week period), double-blind, parallel-group, efficacy and safety study in chronic obstructive pulmonary disease (COPD) patients. Participants randomised to the placebo arm will be randomly re-assigned to one of the four active treatments after completing the 12-week period.

Participant flow — Overall Study
MilestoneFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Started4142494444
Completed00000
Not completed4142494444
Withdrew: Trial termination for strategic reasons4140444238
Withdrew: Adverse event00212
Withdrew: Refused to continue taking the drug00202
Withdrew: Lost to follow-up01010
Withdrew: Lack of efficacy01102

Outcome measures

PrimaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period

Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)

Time frame:
At baseline and week 12
Reported as:
Mean · Litres (L)
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period1.530 ± 0.5980.990 ± 0.283—1.905 ± 0.5200.640 ± 0.537
PrimaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

Change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 min time point just prior to inhalation of the morning dose of randomised treatment.

Time frame:
At baseline and week 24

No measurements were reported for this outcome.

PrimaryForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period

Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 12-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 12 - trough FEV1 at baseline.

Time frame:
At baseline and at week 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres (L)
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment Period1.659 ± 0.6331.048 ± 0.338—1.948 ± 0.5210.802 ± 0.545
PrimaryForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 24-week Treatment Period

Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response at the end of the 24-week treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 24 - trough FEV1 at baseline.

Time frame:
At baseline and at week 24: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.

No measurements were reported for this outcome.

PrimaryMahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

Time frame:
At the end of week 12
Reported as:
Mean · score on a scale
Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period
score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Mahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 12-week Treatment Period1.000 ± 4.2430.500 ± 3.536—3.333 ± 2.517-2.00 ± 2.828
PrimaryMahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 24-week Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major deterioration) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

Time frame:
At the end of week 24

No measurements were reported for this outcome.

PrimarySt George Respiratory Questionnaire (SGRQ) Total Score at the End of the 24-week Treatment Period (Based Upon Pooled Data From 48-week Sister Studies 1184.14 and 1184.15)

The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. The evaluation SGRQ was planned to be based upon pooled data from 48-week sister studies 1184.14 and 1184.15.

Time frame:
At the end of week 24

No measurements were reported for this outcome.

PrimaryTime to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks

Time from start of treatment to first moderate to severe chronic obstructive pulmonary disease (COPD) exacerbation within 48 weeks is presented.

Time frame:
Up to 12 weeks
Reported as:
Median · Days
Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks
DaysFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Within 48 Weeks—19.00 (19.00 to 19.00)41.00 (41.00 to 41.00)—14.00 (14.00 to 14.00)
PrimaryNumber of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 Weeks

Number of patients with moderate to severe chronic obstructive pulmonary disease (COPD) exacerbations within 48 weeks is presented.

Time frame:
Up to 12 weeks.
Reported as:
Number · Count of participants
Number of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 Weeks
Count of participantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
moderate01101
severe00000
SecondaryForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period

Forced Expiratory Volume in one second (FEV1) area under the concentration-time curve from 0 to 8h (AUC0-8h) response after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The FEV1 AUC0-8h is defined as the area under the FEV1 curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FEV1 was assigned to zero time. Trough FEV1 at baseline is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FEV1 AUC0-8h at week 4, 36 or 48 - trough FEV1 at baseline.

Time frame:
At baseline and at week 4: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres (L)
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Forced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment Period1.488 ± 0.6541.259 ± 0.3901.392 ± 0.6051.516 ± 0.4861.095 ± 0.447
SecondaryChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period

Change from baseline in trough Forced Expiratory Volume in one second (FEV1) after 4, 36 and 48 weeks treatment period is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer. Trough FEV1 is defined as the pre-dose FEV1 measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FEV1 response is defined as the change from baseline: Trough FEV1 response = Trough FEV1 - FEV1 (Baseline)

Time frame:
At baseline and week 4
Reported as:
Mean · Litres (L)
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment Period1.365 ± 0.6291.155 ± 0.3591.333 ± 0.5731.408 ± 0.4351.090 ± 0.455
SecondaryChange From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Peak FEV1 is defined as the highest FEV1 reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FEV1 response is defined as the change from baseline: Peak FEV1 response = Peak FEV1 - FEV1 (Baseline)

Time frame:
At baseline and at week 4 and 12: within 3h after inhalation of the morning dose of randomised treatment.
Reported as:
Mean · Litres (L)
Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.293 ± 0.2140.260 ± 0.1780.237 ± 0.1810.330 ± 0.1950.108 ± 0.220
week 120.228 ± 0.2650.200 ± 0.042—0.103 ± 0.5310.185 ± 0.177
SecondaryThe Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment Period

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC AUC0-8h is defined as the area under the FVC curve (AUC) normalized for time. It was calculated as area under the curve from zero time to 8 h using the trapezoidal rule divided by the corresponding duration (i.e. 8 h) to give the results in litres. The trough FVC was assigned to zero time. Trough FVC at baseline is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the first morning dose of randomised treatment at the randomisation visit. Response = FVC AUC0-8h at week 4, 12, 24, 36 or 48 - trough FVC at baseline.

Time frame:
At baseline and at week 4 and 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Millilitres (mL)
The Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment Period
Millilitres (mL)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.451 ± 0.3930.317 ± 0.3340.243 ± 0.3070.381 ± 0.3930.010 ± 0.416
week 120.316 ± 0.4170.009 ± 0.009—0.208 ± 0.4900.328 ± 0.410
SecondaryChange From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment Period

Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC is defined as the pre-dose FVC measured in the clinic at the -10 minutes time point just prior to inhalation of the morning dose of randomised treatment. Trough FVC response is defined as the change from baseline: Trough FVC response = Trough FVC - FVC (Baseline)

Time frame:
At baseline and week 4 and 12
Reported as:
Mean · Millilitres (mL)
Change From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment Period
Millilitres (mL)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.201 ± 0.3320.160 ± 0.2870.175 ± 0.3180.236 ± 0.426-0.037 ± 0.394
week 120.058 ± 0.1730.020 ± 0.085—0.253 ± 0.406-0.060 ± 0.028
SecondaryChange From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48

Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC is defined as the highest FVC reading observed within 3 hours after inhalation of the morning dose of randomised treatment. Peak FVC response is defined as the change from baseline: Peak FVC response = Peak FVC - FVC (Baseline)

Time frame:
At baseline and at week 4 and 12: within 3 hours after inhalation of the morning dose of randomised treatment.
Reported as:
Mean · Millilitres (mL)
Change From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48
Millilitres (mL)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.592 ± 0.4200.462 ± 0.3130.401 ± 0.3610.544 ± 0.4100.178 ± 0.480
week 120.385 ± 0.5030.125 ± 0.021—0.398 ± 0.6150.420 ± 0.438
SecondaryForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4

Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 4 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.

Time frame:
At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres (L)
Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours1.365 ± 0.6291.155 ± 0.3591.333 ± 0.5731.408 ± 0.4351.089 ± 0.447
30 minutes1.463 ± 0.6541.228 ± 0.4061.390 ± 0.5991.546 ± 0.4781.091 ± 0.437
1 hour1.487 ± 0.6711.281 ± 0.4231.414 ± 0.5981.564 ± 0.5081.113 ± 0.447
2 hours1.495 ± 0.6411.266 ± 0.3931.430 ± 0.6151.561 ± 0.5301.100 ± 0.456
3 hours1.505 ± 0.6501.263 ± 0.4061.409 ± 0.6261.559 ± 0.5161.125 ± 0.447
4 hours1.520 ± 0.6701.276 ± 0.3901.404 ± 0.5941.525 ± 0.4931.117 ± 0.450
6 hours1.484 ± 0.6571.267 ± 0.3921.377 ± 0.6121.511 ± 0.4851.091 ± 0.445
8 hours1.455 ± 0.6471.226 ± 0.3891.351 ± 0.6211.428 ± 0.4641.063 ± 0.433
SecondaryForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12

Forced Expiratory Volume in one second (FEV1) at clinic visits at the individual times on week 12 is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. It is measured by a spirometer.

Time frame:
At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres (L)
Forced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours1.530 ± 0.5980.990 ± 0.283—1.905 ± 0.5200.640 ± 0.537
30 minutes1.575 ± 0.5791.050 ± 0.311—1.960 ± 0.5180.805 ± 0.587
1 hour1.643 ± 0.6501.090 ± 0.297—1.993 ± 0.4991.790 ± 0.566
2 hours1.675 ± 0.6301.120 ± 0.368—1.988 ± 0.4940.800 ± 0.566
3 hours1.650 ± 0.6141.095 ± 0.431—2.005 ± 0.4780.815 ± 0.502
4 hours1.703 ± 0.6421.030 ± 0.354—1.963 ± 0.4970.805 ± 0.516
6 hours1.658 ± 0.6591.010 ± 0.255—1.908 ± 0.5460.823 ± 0.562
8 hours1.673 ± 0.6270.960 ± 0.339—1.885 ± 0.6010.795 ± 0.544
SecondaryForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4

Forced Vital Capacity (FVC) at clinic visits at the individual times on week 4 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.

Time frame:
At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Millilitres (mL)
Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4
Millilitres (mL)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours2.864 ± 1.0942.680 ± 0.7362.738 ± 0.8873.018 ± 0.7782.394 ± 0.710
30 minutes3.041 ± 1.1002.761 ± 0.8262.803 ± 0.9013.200 ± 0.7852.436 ± 0.832
1 hour3.123 ± 1.1162.887 ± 0.8452.843 ± 0.9363.216 ± 0.7982.464 ± 0.772
2 hours3.133 ± 1.1062.870 ± 0.8272.888 ± 0.9293.234 ± 0.8162.409 ± 0.842
3 hours3.140 ± 1.1062.840 ± 0.8052.848 ± 0.9573.189 ± 0.7712.437 ± 0.821
4 hours3.203 ± 1.1832.836 ± 0.8162.827 ± 0.9173.156 ± 0.7702.439 ± 0.799
6 hours3.109 ± 1.1532.856 ± 0.8102.767 ± 0.9403.162 ± 0.8402.423 ± 0.841
8 hours3.043 ± 1.1412.806 ± 0.7952.717 ± 0.9893.061 ± 0.8722.346 ± 0.826
SecondaryForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12

Forced Vital Capacity (FVC) at clinic visits at the individual times on week 12 is presented. Forced Vital Capacity (FVC) is the volume of air (measured in millilitres) which can be forcibly exhaled from the lungs after taking the deepest breath possible.

Time frame:
At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Millilitres (mL)
Forced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12
Millilitres (mL)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours3.095 ± 1.0011.920 ± 0.580—3.838 ± 1.0471.455 ± 0.983
30 minutes3.300 ± 1.1661.940 ± 0.396—3.983 ± 1.1771.800 ± 0.636
1 hour3.313 ± 1.1571.980 ± 0.467—3.795 ± 1.1651.795 ± 0.573
2 hours3.378 ± 1.2271.980 ± 0.410—3.863 ± 1.0471.915 ± 0.544
3 hours3.333 ± 1.2751.960 ± 0.566—3.865 ± 1.1071.875 ± 0.431
4 hours3.425 ± 1.2581.880 ± 0.495—3.753 ± 1.0041.820 ± 0.566
6 hours3.383 ± 1.1991.890 ± 0.481—3.730 ± 1.1961.858 ± 0.527
8 hours3.308 ± 1.1551.795 ± 0.516—3.728 ± 1.1551.895 ± 0.488
SecondaryPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4

Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 4 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

Time frame:
At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres/minute (L/min)
Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4
Litres/minute (L/min)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours244.269 ± 107.320219.357 ± 79.168226.138 ± 92.890270.100 ± 89.409201.148 ± 70.055
30 minutes255.462 ± 109.075231.607 ± 91.267230.034 ± 97.724286.833 ± 96.007199.259 ± 75.244
1 hour261.462 ± 114,347233.929 ± 87.890234.517 ± 98.536296.967 ± 104.571197.222 ± 72.697
2 hours268.962 ± 118.729242.386 ± 90.918245.310 ± 99.846304.733 ± 103.822198.370 ± 74.688
3 hours262.923 ± 117.668238.000 ± 90.849240.793 ± 98.726300.700 ± 109.300203.889 ± 79.862
4 hours268.346 ± 120.842245.560 ± 88.435242.759 ± 96.366302.511 ± 111.479200.370 ± 77.459
6 hours261.538 ± 122.880243.429 ± 91.812233.310 ± 104.031291.833 ± 103.339195.148 ± 75.621
8 hours259.346 ± 119.517236.464 ± 92.758240.103 ± 100.926279.800 ± 101.988195.593 ± 77.674
SecondaryPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12

Peak expiratory flow (PEF) rate at clinic visits at the individual times on week 12 is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

Time frame:
At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
Reported as:
Mean · Litres/minute (L/min)
Peak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12
Litres/minute (L/min)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
0 hours280.000 ± 142.164189.000 ± 73.539—368.750 ± 87.717122.500 ± 132.229
30 minutes294.250 ± 169.230179.500 ± 60.104—375.750 ± 103.035171.500 ± 88.388
1 hour300.500 ± 158.437190.000 ± 65.054—383.250 ± 80.081141.000 ± 148.492
2 hours313.250 ± 172.386195.500 ± 74.246—391.500 ± 81.668172.500 ± 159.099
3 hours304.500 ± 165.291178.500 ± 86.974—385.500 ± 83.927165.000 ± 104.652
4 hours302.250 ± 173.899189.500 ± 105.359—377.000 ± 87.189186.000 ± 87.681
6 hours310.250 ± 173.893174.000 ± 67.882—365.000 ± 88.871198.750 ± 106.420
8 hours296.750 ± 181.926183.000 ± 108.894—372.750 ± 120.453207.000 ± 118.794
SecondaryWeekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)

Weekly mean morning pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their morning study medications prior to each morning PEF measurement.

Time frame:
At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Reported as:
Mean · Litres / minute (L/min)
Weekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)
Litres / minute (L/min)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 1225.9 ± 127.91230.1 ± 101.15218.3 ± 92.13259.9 ± 112.47190.9 ± 83.92
week 2231.3 ± 134.04220.2 ± 101.3223.6 ± 96.95262.1 ± 108.16192.1 ± 81.01
week 3236.9 ± 139.85222.4 ± 98.34225.3 ± 99.27265.6 ± 112.97190.4 ± 82.71
week 4233.1 ± 143.04229.4 ± 96.99226.3 ± 101.88266.7 ± 113.45196.3 ± 92.13
week 5232.1 ± 138.20221.1 ± 105.67221.4 ± 102.96279.1 ± 104.92187.5 ± 87.08
week 6229.9 ± 140.33219.7 ± 101.17219.3 ± 106.89278.2 ± 109.25194.9 ± 94.60
week 7246.6 ± 136.21225.4 ± 101.29230.3 ± 113.45278.6 ± 109.83193.1 ± 94.19
week 8260.1 ± 135.13243.7 ± 111.59236.2 ± 120.61269.1 ± 106.93190.1 ± 102.04
week 9245.3 ± 139.43250.8 ± 117.74236.0 ± 117.38277.4 ± 107.30203.3 ± 120.71
week 10252.2 ± 146.94217.3 ± 74.54229.6 ± 106.37296.2 ± 106.31153.8 ± 71.45
week 11266.7 ± 157.37212.8 ± 71.11219.2 ± 105.21310.5 ± 118.90163.3 ± 70.18
week 12251.7 ± 145.50213.6 ± 84.51207.3 ± 105.93325.5 ± 105.79166.1 ± 70.81
week 13311.2 ± 196.52168.8 ± 109.64—376.3 ± 93.14—
week 14327.3241.7—328.3 ± 0.81—
SecondaryWeekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)

Weekly mean evening pre-dose peak expiratory flows (PEFs) is presented. Patients received an electronic diary. Peak expiratory flows (PEFs) were determined individually at home and reported by the patient. The pulmonary function test was obtained by spirometry. The best of three efforts was defined as the highest PEF. Patients did not take their evening study medications prior to each evening PEF measurement.

Time frame:
At week 1 to 14, each evening between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Reported as:
Mean · Litres / minute (L/min)
Weekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)
Litres / minute (L/min)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 1246.6 ± 129.31249.0 ± 103.75224.1 ± 92.95271.3 ± 111.79205.2 ± 81.10
week 2250.4 ± 136.64243.3 ± 100.91229.8 ± 93.81275.3 ± 108.00208.5 ± 74.46
week 3255.4 ± 140.86243.3 ± 101.52228.2 ± 99.94277.1 ± 116.62207.3 ± 79.52
week 4257.1 ± 145.90249.2 ± 101.77225.9 ± 102.01276.7 ± 116.87205.9 ± 89.26
week 5250.4 ± 144.68238.1 ± 102.07229.4 ± 103.43286.2 ± 112.48210.5 ± 89.21
week 6249.9 ± 143.58237.4 ± 101.29227.0 ± 102.44279.1 ± 116.73203.7 ± 89.21
week 7254.8 ± 142.14241.0 ± 102.97238.4 ± 107.19283.3 ± 123.29208.3 ± 94.49
week 8274.9 ± 148.12258.7 ± 115.92229.3 ± 112.63283.8 ± 116.20194.1 ± 100.58
week 9267.5 ± 150.16239.8 ± 86.10230.8 ± 111.89293.4 ± 112.33205.0 ± 111.36
week 10273.5 ± 155.67243.3 ± 76.29242.1 ± 105.29311.8 ± 114.71165.4 ± 62.62
week 11279.6 ± 168.14227.4 ± 68.57220.0 ± 101.51311.7 ± 116.24171.7 ± 70.29
week 12272.6 ± 158.77221.8 ± 83.28194.0 ± 101.34333.0 ± 112.61160.0 ± 86.92
week 13337.1 ± 214.03201.8 ± 112.55—397.5 ± 114.15—
week 14365.5290.3—349.8 ± 15.56—
SecondaryPeak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48

Peak expiratory flow (PEF) are determined by spirometry at clinic visits (week 4, 12, 18, 24, 36 and 48) is presented. Spirometry will begin between 07:00 and 10:00 a.m. PEF measurements will be performed 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment. The measurements scheduled at 30 and 60 minutes after inhalation will be obtained within ± 5 minutes of the specified time-points.Measurements scheduled at 2-8 hours after inhalation will be obtained within ± 10 minutes of the specified time-points.

Time frame:
At week 4 and 12: 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment.
Reported as:
Mean · Litres/minute (L/min)
Peak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48
Litres/minute (L/min)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 4268.962 ± 118.729245.560 ± 88.435245.310 ± 99.846304.733 ± 103.822203.889 ± 79.862
week 12313.250 ± 172.386195.500 ± 74.246—391.500 ± 81.668207.000 ± 118.794
SecondaryWeekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)

Weekly mean morning pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their morning study medications prior to each morning FEV1 measurement.

Time frame:
At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Reported as:
Mean · Litres (L)
Weekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 11.3 ± 0.711.1 ± 0.381.2 ± 0.521.4 ± 0.521.1 ± 0.41
week 21.3 ± 0.751.0 ± 0.341.2 ± 0.491.4 ± 0.491.0 ± 0.38
week 31.4 ± 0.741.1 ± 0.371.2 ± 0.471.4 ± 0.511.1 ± 0.39
week 41.3 ± 0.731.1 ± 0.371.3 ± 0.521.4 ± 0.541.1 ± 0.45
week 51.3 ± 0.771.0 ± 0.321.2 ± 0.511.4 ± 0.541.0 ± 0.38
week 61.4 ± 0.771.0 ± 0.321.2 ± 0.511.4 ± 0.591.0 ± 0.38
week 71.4 ± 0.761.0 ± 0.341.3 ± 0.531.4 ± 0.571.0 ± 0.39
week 81.5 ± 0.771.1 ± 0.361.3 ± 0.551.4 ± 0.601.0 ± 0.37
week 91.5 ± 0.701.1 ± 0.351.3 ± 0.521.5 ± 0.591.0 ± 0.46
week 101.4 ± 0.651.1 ± 0.321.3 ± 0.471.5 ± 0.690.8 ± 0.24
week 111.5 ± 0.691.0 ± 0.251.3 ± 0.491.5 ± 0.730.8 ± 0.21
week 121.4 ± 0.511.0 ± 0.381.2 ± 0.451.6 ± 0.720.8 ± 0.23
week 131.3 ± 0.680.8 ± 0.34—2.0 ± 1.07—
week 141.40.8—1.6 ± 0.05—
SecondaryWeekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)

Weekly mean evening pre-dose Forced expiratory volume in one second (FEV1) is presented. FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements are performed individually at home and reported by the patient. It is measured by a spirometer. The best of three efforts was defined as the highest FEV1. Patients did not take their evening study medications prior to each evening FEV1 measurement.

Time frame:
At week 1 to 14, each morning between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
Reported as:
Mean · Litres (L)
Weekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)
Litres (L)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 11.4 ± 0.731.2 ± 0.461.2 ± 0.481.4 ± 0.551.1 ± 0.40
week 21.4 ± 0.751.2 ± 0.421.2 ± 0.471.4 ± 0.481.1 ± 0.40
week 31.4 ± 0.771.1 ± 0.391.2 ± 0.491.4 ± 0.541.1 ± 0.42
week 41.4 ± 0.761.2 ± 0.401.3 ± 0.481.5 ± 0.541.1 ± 0.44
week 51.4 ± 0.781.1 ± 0.351.3 ± 0.511.4 ± 0.531.1 ± 0.39
week 61.4 ± 0.791.1 ± 0.341.3 ± 0.491.4 ± 0.611.1 ± 0.40
week 71.4 ± 0.731.1 ± 0.361.3 ± 0.501.4 ± 0.581.1 ± 0.39
week 81.5 ± 0.771.2 ± 0.411.3 ± 0.511.5 ± 0.661.0 ± 0.39
week 91.6 ± 0.781.1 ± 0.421.3 ± 0.471.5 ± 0.631.0 ± 0.47
week 101.5 ± 0.661.2 ± 0.381.4 ± 0.441.5 ± 0.720.9 ± 0.25
week 111.6 ± 0.691.1 ± 0.351.2 ± 0.391.6 ± 0.720.9 ± 0.29
week 121.4 ± 0.551.1 ± 0.371.2 ± 0.421.6 ± 0.800.9 ± 0.35
week 131.4 ± 0.660.9 ± 0.22—2.2 ± 1.09—
week 141.61.0—1.8 ± 0.07—
SecondaryWeekly Mean Number Per Day of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

Weekly mean number per day of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

Time frame:
Weekly up to week 14: per day (24 hours period)
Reported as:
Mean · count of puffs per day
Weekly Mean Number Per Day of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
count of puffs per dayFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 11.8 ± 2.761.7 ± 2.632.6 ± 3.901.9 ± 2.674.7 ± 4.57
week 21.3 ± 2.132.0 ± 2.862.3 ± 3.621.8 ± 2.815.3 ± 5.13
week 31.4 ± 2.291.9 ± 2.971.9 ± 3.321.4 ± 2.345.1 ± 5.24
week 41.1 ± 2.221.5 ± 2.892.5 ± 3.651.7 ± 2.485.0 ± 5.09
week 51.1 ± 2.412.0 ± 2.942.7 ± 3.911.2 ± 1.604.2 ± 4.14
week 61.2 ± 2.261.9 ± 2.712.4 ± 3.741.3 ± 1.804.7 ± 4.71
week 71.1 ± 2.432.1 ± 3.112.1 ± 3.611.8 ± 2.445.4 ± 5.25
week 81.0 ± 2.491.7 ± 2.382.4 ± 4.111.4 ± 2.495.7 ± 5.78
week 91.1 ± 2.581.7 ± 2.571.9 ± 3.881.4 ± 2.095.4 ± 5.42
week 100.3 ± 0.721.7 ± 2.311.6 ± 3.991.6 ± 1.853.7 ± 3.00
week 110.7 ± 1.421.9 ± 2.512.7 ± 4.251.6 ± 1.862.7 ± 2.38
week 121.3 ± 1.781.5 ± 1.901.7 ± 3.081.7 ± 2.642.3 ± 2.93
week 131.0 ± 1.651.1 ± 0.20—1.3 ± 2.69—
week 140.01.3—0.6 ± 0.91—
SecondaryWeekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

Weekly mean number at daytime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

Time frame:
Weekly up to week 14: at daytime (from morning dose till evening dose of study medication)
Reported as:
Mean · count of puffs
Weekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
count of puffsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 11.2 ± 1.751.3 ± 1.801.9 ± 3.001.3 ± 1.773.0 ± 3.11
week 21.0 ± 1.601.4 ± 1.861.8 ± 2.971.1 ± 1.773.2 ± 3.21
week 30.9 ± 1.731.3 ± 1.951.7 ± 3.040.9 ± 1.483.0 ± 3.31
week 41.0 ± 1.831.0 ± 1.871.9 ± 3.181.0 ± 1.553.1 ± 3.48
week 50.8 ± 1.801.4 ± 1.962.1 ± 3.190.7 ± 0.912.7 ± 2.75
week 60.8 ± 1.701.2 ± 1.681.9 ± 3.301.0 ± 1.162.9 ± 3.09
week 70.9 ± 1.861.3 ± 1.901.7 ± 3.181.1 ± 1.293.3 ± 3.54
week 80.9 ± 2.001.2 ± 1.692.0 ± 3.660.8 ± 1.303.4 ± 3.67
week 90.7 ± 1.951.3 ± 1.951.6 ± 3.500.9 ± 1.223.5 ± 3.60
week 100.3 ± 0.761.2 ± 1.401.4 ± 3.981.1 ± 1.142.8 ± 2.35
week 110.5 ± 0.881.3 ± 1.742.2 ± 4.211.0 ± 1.132.1 ± 2.67
week 120.6 ± 0.951.0 ± 1.200.9 ± 1.451.0 ± 1.361.8 ± 2.95
week 130.4 ± 0.661.0 ± 0.26—0.7 ± 1.44—
week 140.01.0—0.6 ± 0.91—
SecondaryWeekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)

Weekly mean number at nighttime of puffs of as-needed salbutamol/albuterol metered dose inhaler (MDI) is presented. Patients inhaled puffs of rescue medication of 100 micrograms (μg) salbutamol/albuterol metered dose inhaler (MDI).

Time frame:
Weekly up to week 14: at nighttime (from evening dose till morning dose of study medication)
Reported as:
Mean · count of puffs
Weekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)
count of puffsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 10.6 ± 1.090.4 ± 1.040.7 ± 1.240.6 ± 1.061.6 ± 1.69
week 20.4 ± 0.760.7 ± 1.180.6 ± 1.220.7 ± 1.182.0 ± 2.18
week 30.4 ± 0.710.7 ± 1.140.4 ± 0.770.5 ± 1.022.0 ± 2.26
week 40.3 ± 0.600.5 ± 1.150.6 ± 1.050.7 ± 1.221.9 ± 1.99
week 50.3 ± 0.620.6 ± 1.190.7 ± 1.170.4 ± 0.771.5 ± 1.83
week 60.3 ± 0.610.6 ± 1.180.5 ± 0.890.6 ± 0.851.8 ± 1.97
week 70.3 ± 0.630.7 ± 1.350.4 ± 0.830.8 ± 1.372.1 ± 2.07
week 80.3 ± 0.670.4 ± 1.070.4 ± 0.850.6 ± 1.252.2 ± 2.57
week 90.4 ± 0.800.4 ± 0.640.3 ± 0.880.5 ± 0.981.9 ± 2.46
week 100.1 ± 0.300.5 ± 0.990.2 ± 0.370.6 ± 0.920.9 ± 1.14
week 110.3 ± 0.580.6 ± 0.930.4 ± 0.720.6 ± 0.840.6 ± 0.63
week 120.6 ± 1.010.4 ± 0.871.0 ± 2.000.7 ± 1.310.5 ± 0.55
week 130.6 ± 0.990.2 ± 0.06—0.6 ± 1.25—
week 140.00.3—0.0 ± 0.00—
SecondaryWeekly Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Nighttime Awakenings

Weekly mean number of chronic obstructive pulmonary disease (COPD)-related nighttime awakenings is presented.

Time frame:
Per week, up to 14 weeks
Reported as:
Mean · count of awakenings per nighttime
Weekly Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Nighttime Awakenings
count of awakenings per nighttimeFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 10.3 ± 0.540.1 ± 0.410.2 ± 0.500.2 ± 0.430.3 ± 0.49
week 20.2 ± 0.300.2 ± 0.480.2 ± 0.400.1 ± 0.340.4 ± 0.49
week 30.1 ± 0.180.2 ± 0.540.2 ± 0.400.1 ± 0.310.3 ± 0.49
week 40.1 ± 0.320.2 ± 0.560.1 ± 0.260.1 ± 0.210.4 ± 0.58
week 50.1 ± 0.260.2 ± 0.490.1 ± 0.120.1 ± 0.300.3 ± 0.52
week 60.1 ± 0.380.2 ± 0.510.1 ± 0.210.3 ± 0.770.3 ± 0.52
week 70.1 ± 0.220.1 ± 0.280.1 ± 0.190.3 ± 0.770.5 ± 0.61
week 80.0 ± 0.090.1 ± 0.420.1 ± 0.150.3 ± 0.810.5 ± 0.62
week 90.1 ± 0.250.1 ± 0.430.1 ± 0.270.3 ± 0.710.5 ± 0.71
week 100.0 ± 0.050.1 ± 0.440.0 ± 0.140.2 ± 0.510.4 ± 0.56
week 110.2 ± 0.280.1 ± 0.320.0 ± 0.000.2 ± 0.490.4 ± 0.67
week 120.2 ± 0.400.1 ± 0.420.0 ± 0.000.3 ± 0.670.3 ± 0.41
week 130.1 ± 0.250.0 ± 0.00—0.2 ± 0.38—
week 140.00.0—0.0 ± 0.00—
SecondaryMahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. It is based on the criteria of the various grades for change in functional impairment (any activities started or stopped?), change in magnitude of task (What activities cause breathlessness now?) and change in magnitude of effort (Need to pause while performing activities?), which causes breathlessness, each ranging from grade -3 (major detonation) to +3 (major improvement). The Transition Dyspnoea Index (TDI) focal score was calculated as the sum of these three components of the TDI, i.e. change in Functional Impairment, in Magnitude of Task and in Magnitude of Effort. Consequently, TDI ranges from -9 to +9 with a higher score indicating improvement.

Time frame:
At week 4
Reported as:
Mean · score on a scale
Mahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period
score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Mahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment Period0.346 ± 1.6720.857 ± 2.4600.966 ± 1.9731.167 ± 2.321-1.407 ± 2.791
SecondaryMahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - functional impairment is based on the criteria of change in functional impairment (any activities started or stopped?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

Time frame:
At the end of week 4 and 12.
Reported as:
Mean · score on a scale
Mahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.038 ± 0.6620.250 ± 0.7010.310 ± 0.7120.400 ± 0.814-0.481 ± 1.014
week 120.500 ± 1.0000.000 ± 1.414—1.333 ± 0.577-0.500 ± 0.707
SecondaryMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of task is based on the criteria of change in magnitude of task (What activities cause breathlessness now?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

Time frame:
At the end of week 4 and 12.
Reported as:
Mean · score on a scale
Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.269 ± 0.6670.393 ± 0.8750.345 ± 0.6700.433 ± 0.858-0.296 ± 0.993
week 120.250 ± 0.2580.500 ± 0.707—1.000 ± 1.000-0.500 ± 0.707
SecondaryMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period

The Mahler Dyspnoea questionnaire is an instrument which measures the severity of breathlessness (shortness of breath) change from the baseline state. The Mahler Transition Dyspnoea Index (TDI) domain score - magnitude of effort is based on the criteria of change in magnitude of effort (Need to pause while performing activities?) which causes breathlessness, ranging from grade -3 (major deterioration) to +3 (major improvement).

Time frame:
At the end of week 4 and 12.
Reported as:
Mean · score on a scale
Mahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment Period
score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 40.038 ± 0.6620.214 ± 0.9950.310 ± 0.7610.333 ± 0.884-0.630 ± 0.967
week 120.250 ± 2.0620.000 ± 1.414—1.000 ± 1.000-1.000 ± 1.414
SecondarySt George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 Weeks

The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

Time frame:
At week 4 and 12.
Reported as:
Mean · Score on a scale
St George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 Weeks
Score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 437.611 ± 19.08841.649 ± 18.43938.070 ± 16.66341.107 ± 19.45352.655 ± 22.068
week 1245.631 ± 34.96140.625 ± 25.601—24.167 ± 19.21455.332 ± 30.430
SecondarySt George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 Weeks

The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The impact domain score is a part of the SGRQ that measures the impact of disease on daily life. Its scores range from 0 to 100, with higher scores indicating more limitations.

Time frame:
At week 4 and 12.
Reported as:
Mean · Score on a scale
St George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 Weeks
Score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 426.733 ± 18.88129.872 ± 17.85826.145 ± 16.48430.515 ± 20.26941.308 ± 23.463
week 1236.576 ± 33.48926.686 ± 22.801—13.830 ± 14.37342.214 ± 25.362
SecondarySt George Respiratory Questionnaire (SGRQ) Activity Domain Score Collected at 4, 12, 36 and 48 Weeks

The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The activity domain score is a part of the SGRQ that measures the activity of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.

Time frame:
At week 4 and 12.
Reported as:
Mean · Score on a scale
St George Respiratory Questionnaire (SGRQ) Activity Domain Score Collected at 4, 12, 36 and 48 Weeks
Score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 453.592 ± 22.37961.836 ± 20.57958.923 ± 23.07060.663 ± 22.44968.334 ± 23.000
week 1253.254 ± 38.36960.768 ± 17.352—41.428 ± 18.06373.844 ± 36.990
SecondarySt George Respiratory Questionnaire (SGRQ) Symptoms Domain Score Collected at 4, 12, 36 and 48 Weeks

The St George Respiratory Questionnaire (SGRQ) is designed as a supervised self-administered questionnaire that determines the impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The symptoms domain score is a part of the SGRQ that measures the symptoms of the patient. Its scores range from 0 to 100, with higher scores indicating more limitations.

Time frame:
At week 4 and 12.
Reported as:
Mean · Score on a scale
St George Respiratory Questionnaire (SGRQ) Symptoms Domain Score Collected at 4, 12, 36 and 48 Weeks
Score on a scaleFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
week 443.178 ± 25.48742.955 ± 24.83738.346 ± 21.29939.070 ± 26.93960.312 ± 24.383
week 1260.664 ± 34.20248.423 ± 49.610—25.706 ± 38.95163.479 ± 34.656
SecondaryNumber of Patients With Adverse Events Within the 48-week Treatment Period

Number of patients with adverse events within the 48-week treatment period is presented. A patient may be counted in more than one seriousness criterion.

Time frame:
From randomisation till end of treatment, up to 12 weeks.
Reported as:
Number · Count of participants
Number of Patients With Adverse Events Within the 48-week Treatment Period
Count of participantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
any adverse event (AE)8101059
severe AE10310
investigator-defined drug-related AE15102
other significant AE (according to ICH-E3)11002
AE leading to discontinuation of trial drug00212
significant AE (pre-specified events)00000
serious AE (fatal)00110
serious AE (life-threatening)00000
serious AE (disability)00000
serious AE (required hospitalisation)00401
serious AE (prolonged hospitalisation)00000
serious AE (congenital anomaly)00000
serious AE (other)00000
SecondaryNumber of Patients With Marked Changes in Vital Signs (Decrease) by Clinic Visit

Number of patients with marked changes in vital signs (decrease) by clinic visit is presented. Vital signs: pulse rate and blood pressure (BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Decrease: Below 100 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Diastolic BP Decrease: Below 60 mmHg if not at that level at baseline and a decrease of greater than 10 mmHg below baseline. Pulse rate Decrease: Below 60 bpm if not at that level at baseline and a decrease of greater than 10 bpm below baseline.

Time frame:
At baseline, week 4 and week 12.
Reported as:
Number · Count of participants
Number of Patients With Marked Changes in Vital Signs (Decrease) by Clinic Visit
Count of participantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
systolic BP (week 4)12011
systolic BP (week12)10001
diastolic BP (week 4)22111
diastolic BP (week 12)10000
pulse rate (week 4)01102
pulse rate (week 12)00000
SecondaryNumber of Patients With Marked Changes in Vital Signs (Increase) by Clinic Visit

Number of patients with marked changes in vital signs (increase) by clinic visit is presented. Vital signs: pulse rate and blood pressure 8BP) (after five minutes rest in seated position) recorded pre-dose on each pulmonary function test-day and in conjunction with spirometry for the first 3 hours post-dosing. Systolic BP Increase : An increase of 25 mmHg or more above baseline. Diastolic BP Increase: Above 90 mmHg at baseline and an increase of greater than 10 mmHg above baseline. Pulse rate Increase : Greater than 100 bpm if not at that level at baseline and an increase greater than 10 above baseline.

Time frame:
At baseline, week 4 and week 12.
Reported as:
Number · Count of participants
Number of Patients With Marked Changes in Vital Signs (Increase) by Clinic Visit
Count of participantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
systolic BP (week 4)31313
systolic BP (week 12)00000
diastolic BP (week 4)13422
diastolic BP (week 12)00010
pulse rate (week 4)00001
pulse rate (week 12)00000
SecondaryNumber of Patients With Abnormal Haematology at the End of the 12-week Treatment Period

Number of patients with abnormal haematology at the end of the 12-week treatment period is presented.

Time frame:
At the end of the 12-week treatment period.
Reported as:
Count of participants · Participants
Number of Patients With Abnormal Haematology at the End of the 12-week Treatment Period
ParticipantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Increased white blood cell count10000
Decreased white blood cell count00000
Basophils increase00000
Basophils decrease00000
Eosinophils increase00010
Eosinophils decrease00000
Absolute eosinophils increase00000
Absolute eosinophils decrease00000
Haematocrit increase00001
Haematocrit decrease00000
Haemoglobin increase00000
Haemoglobin decrease00000
Absolute lymphocyte increase00000
Absolute lymphocyte decrease00000
Lymphocytes increase00000
Lymphocytes decrease10000
Absolute monocytes increase00000
Absolute monocytes decrease00000
Monocytes increase00000
Monocytes decrease10000
Absolute neutrophils increase10011
Absolute neutrophils decrease00000
Neutrophils increase10011
Neutrophils decrease00000
Platelets increase01000
Platelets decrease00000
Red blood cell morphology (qualitative) increase00000
Red blood cell morphology (qualitative) decrease00000
Red blood cell count increase00000
Red blood cell count decrease00000
Total eosinophil count increase00000
Total eosinophil count decrease00000
White blood cell morphology (qualitative) increase00000
White blood cell morphology (qualitative) decrease00000
SecondaryNumber of Patients With Abnormal Blood Chemistry at the End of the 12-week Treatment Period

Number of patients with abnormal blood chemistry at the end of the 12-week treatment period is presented.

Time frame:
At the end of the 12-week treatment period.
Reported as:
Count of participants · Participants
Number of Patients With Abnormal Blood Chemistry at the End of the 12-week Treatment Period
ParticipantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Alanine aminotransferase increase00001
Alanine amoínotransferase decrease00000
Aspartate aminotransferase increase00000
Aspartate aminotransferase decrease00000
Albumin increase00000
Albumin decrease00000
Alkaline phosphatase increase00000
Alkaline phosphatase decrease00000
Total bilirubin increase00000
Total bilirubin decrease00000
Blood urea nitrogen increase00000
Blood urea nitrogen decrease00000
Calcium increase00000
Calcium decrease00000
Creatinine increase00000
Creatinine decrease00000
Gamma glutamyltransferase increase10010
Gamma glutamyltransferase decrease00000
Glucose increase00000
Glucose decrease00000
Lactate dehydrogenase increase00000
Lactate dehydrogenase decrease00000
Phosphate increase00000
Phosphate decrease00000
Potassium increase00000
Potassium decrease00000
Total protein increase00000
Total protein decrease00000
Sodium increase00000
Sodium decrease01000
Uric acid increase10010
Uric acid decrease00000
SecondaryNumber of Patients With Abnormal Urinalysis at the End of the 12-week Treatment Period

Number of patients with abnormal urinalysis at the end of the 12-week treatment period is presented.

Time frame:
At the end of the 12-week treatment period.
Reported as:
Count of participants · Participants
Number of Patients With Abnormal Urinalysis at the End of the 12-week Treatment Period
ParticipantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Urine blood (qualitative) increase00000
Urine blood (qualitative) decrease00000
Urine glucose (qualitative) increase00000
Urine glucose (qualitative) decrease00000
Urine pH increase00000
Urine pH decrease00000
Urine protein (qualitative) increase00010
Urine protein (qualitative) decrease00000
Urine specific gravity increase00000
Urine specific gravity decrease00000
SecondaryVital Status of Randomised Patients

Vital status of randomised patients is presented.

Time frame:
Up to 48 weeks.

No measurements were reported for this outcome.

SecondaryNumber of Days in Hospital Within the 48-week Treatment Period

Number of days in hospital within the 48-week treatment period is presented.

Time frame:
Up to 12 weeks.
Reported as:
Mean · days
Number of Days in Hospital Within the 48-week Treatment Period
daysFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Number of Days in Hospital Within the 48-week Treatment Period0.0 ± 0.00.0 ± 0.00.1 ± 0.90.0 ± 0.00.0 ± 0.0
SecondaryNumber of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period

Number of unscheduled health care provider visits within the 48-week treatment period is presented.

Time frame:
Up to 12 weeks.
Reported as:
Mean · count of visits
Number of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period
count of visitsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Number of Unscheduled Health Care Provider Visits Within the 48-week Treatment Period0.02 ± 0.160.31 ± 0.870.04 ± 0.200.16 ± 0.430.16 ± 0.53
SecondaryNumber of Emergency Room Visits Within the 48-week Treatment Period

Number of emergency room visits within the 48-week treatment period is presented.

Time frame:
Up to 12 weeks.
Reported as:
Mean · count of visits
Number of Emergency Room Visits Within the 48-week Treatment Period
count of visitsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Number of Emergency Room Visits Within the 48-week Treatment Period0.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
SecondaryNumber of Days in Intensive Care Unit Within the 48-week Treatment Period

Number of days in intensive care unit within the 48-week treatment period is presented.

Time frame:
Up to 12 weeks.
Reported as:
Mean · days
Number of Days in Intensive Care Unit Within the 48-week Treatment Period
daysFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Number of Days in Intensive Care Unit Within the 48-week Treatment Period0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
SecondaryNumber of Patients Receiving Concomitant Medication

Number of patients receiving concomitant medication is presented. Concomitant medication was observed for rerandomized placebo patients during placebo treatment and on-treatment periods.

Time frame:
Up to 12 weeks.
Reported as:
Number · Count of participants
Number of Patients Receiving Concomitant Medication
Count of participantsFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Number of Patients Receiving Concomitant Medication3835444341

Adverse events

Collected over From first dose of study drug until end of week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC Tiotropium / Salmeterol (T+S_PE)0/43 (0%)0/43 (0%)1/43 (2.3%)
Tiotropium (Tio18GEL)0/42 (0%)1/42 (2.4%)1/42 (2.4%)
Salmeterol (Salm25PE)1/49 (2%)5/49 (10.2%)1/49 (2%)
FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)1/44 (2.3%)1/44 (2.3%)0/44 (0%)
Placebo0/44 (0%)3/44 (6.8%)3/44 (6.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/431/420/490/440/44
PalpitationsCardiac disorders0/430/420/490/441/44
Ventricular extrasystolesCardiac disorders0/430/420/490/441/44
Angle closure glaucomaEye disorders0/430/420/490/441/44
SyncopeNervous system disorders0/430/420/490/441/44
ArteriosclerosisVascular disorders0/430/420/491/440/44
Atrial flutterCardiac disorders0/430/421/490/440/44
Myocardial infarctionCardiac disorders0/430/421/490/440/44
Tendon disorderMusculoskeletal and connective tissue disorders0/430/421/490/440/44
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/421/490/440/44
Most frequent other events
Most frequent other events
EventFDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/431/421/490/443/44

Baseline characteristics

The treated set (TS): The treated set consists of all randomised patients who took at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)PlaceboTotal
Mean63.7 ± 9.066.3 ± 9.065.5 ± 9.362.8 ± 9.764.0 ± 8.464.5 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)PlaceboTotal
Female161618131679
Male2526313128141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)PlaceboTotal
Hispanic or Latino001102
Not Hispanic or Latino4142484344218
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FDC Tiotropium / Salmeterol (T+S_PE)Tiotropium (Tio18GEL)Salmeterol (Salm25PE)FDC Tiotropium / Salmeterol + Salmeterol (T+S_PE / S25PE)PlaceboTotal
American Indian or Alaska Native000000
Asian100001
Native Hawaiian or Other Pacific Islander000000
Black or African American211004
White3841484444215
More than one race000000
Unknown or Not Reported000000
08

Study locations

72 sites
  • 1184.14.01013 Boehringer Ingelheim Investigational Site
    Boulder, Colorado, United States
  • 1184.14.01018 Boehringer Ingelheim Investigational Site
    Wheat Ridge, Colorado, United States
  • 1184.14.01006 Boehringer Ingelheim Investigational Site
    Winter Park, Florida, United States
  • 1184.14.01003 Boehringer Ingelheim Investigational Site
    Coeur d'Alene, Idaho, United States
  • 1184.14.01015 Boehringer Ingelheim Investigational Site
    South Bend, Indiana, United States
  • 1184.14.01007 Boehringer Ingelheim Investigational Site
    Lafayette, Louisiana, United States
  • 1184.14.01005 Boehringer Ingelheim Investigational Site
    Bangor, Maine, United States
  • 1184.14.01020 Boehringer Ingelheim Investigational Site
    Edina, Minnesota, United States
  • 1184.14.01009 Boehringer Ingelheim Investigational Site
    Burlington, North Carolina, United States
  • 1184.14.01002 Boehringer Ingelheim Investigational Site
    Cincinnati, Ohio, United States
  • 1184.14.01021 Boehringer Ingelheim Investigational Site
    Toledo, Ohio, United States
  • 1184.14.01012 Boehringer Ingelheim Investigational Site
    East Providence, Rhode Island, United States
  • 1184.14.01017 Boehringer Ingelheim Investigational Site
    Greenville, South Carolina, United States
  • 1184.14.01008 Boehringer Ingelheim Investigational Site
    Spartanburg, South Carolina, United States
  • 1184.14.01014 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1184.14.01022 Boehringer Ingelheim Investigational Site
    Killeen, Texas, United States
  • 1184.14.01001 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1184.14.01010 Boehringer Ingelheim Investigational Site
    Temple, Texas, United States
  • 1184.14.01011 Boehringer Ingelheim Investigational Site
    Richmond, Virginia, United States
  • 1184.14.01019 Boehringer Ingelheim Investigational Site
    Richmond, Virginia, United States
  • 1184.14.43001 Boehringer Ingelheim Investigational Site
    Feldbach, Austria
  • 1184.14.32001 Boehringer Ingelheim Investigational Site
    Brussels, Belgium
  • 1184.14.32004 Boehringer Ingelheim Investigational Site
    Turnhout, Belgium
  • 1184.14.02005 Boehringer Ingelheim Investigational Site
    Calgary, Alberta, Canada
  • 1184.14.02003 Boehringer Ingelheim Investigational Site
    Chilliwack, British Columbia, Canada
  • 1184.14.02010 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1184.14.02001 Boehringer Ingelheim Investigational Site
    Niagara Falls, Ontario, Canada
  • 1184.14.02002 Boehringer Ingelheim Investigational Site
    La Malbaie, Quebec, Canada
  • 1184.14.02008 Boehringer Ingelheim Investigational Site
    Ste-Foy, Quebec, Canada
  • 1184.14.02007 Boehringer Ingelheim Investigational Site
    Saskatoon, Saskatchewan, Canada
  • 1184.14.45001 Boehringer Ingelheim Investigational Site
    Hvidovre, Denmark
  • 1184.14.45002 Boehringer Ingelheim Investigational Site
    København NV, Denmark
  • 1184.14.37202 Boehringer Ingelheim Investigational Site
    Tallinn, Estonia
  • 1184.14.37201 Boehringer Ingelheim Investigational Site
    Tartu, Estonia
  • 1184.14.35802 Boehringer Ingelheim Investigational Site
    Espoo, Finland
  • 1184.14.35801 Boehringer Ingelheim Investigational Site
    HUS, Finland
  • 1184.14.3301A Boehringer Ingelheim Investigational Site
    Brest, France
  • 1184.14.3304A Boehringer Ingelheim Investigational Site
    Marseille, France
  • 1184.14.3302A Boehringer Ingelheim Investigational Site
    Montpellier, France
  • 1184.14.3303A Boehringer Ingelheim Investigational Site
    Perpignan, France
  • 1184.14.3303B Boehringer Ingelheim Investigational Site
    Perpignan, France
  • 1184.14.3303C Boehringer Ingelheim Investigational Site
    Perpignan, France
  • 1184.14.49003 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1184.14.49004 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1184.14.49006 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1184.14.49008 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1184.14.49002 Boehringer Ingelheim Investigational Site
    Hamburg, Germany
  • 1184.14.49007 Boehringer Ingelheim Investigational Site
    Hamburg, Germany
  • 1184.14.49001 Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • 1184.14.30001 Boehringer Ingelheim Investigational Site
    Athens, Greece
  • 1184.14.30004 Boehringer Ingelheim Investigational Site
    Nafplion, Greece
  • 1184.14.30006 Boehringer Ingelheim Investigational Site
    Rethymno, Greece
  • 1184.14.36002 Boehringer Ingelheim Investigational Site
    Debrecen, Hungary
  • 1184.14.36001 Boehringer Ingelheim Investigational Site
    Hodmezövasarhely, Hungary
  • 1184.14.36005 Boehringer Ingelheim Investigational Site
    Komló, Hungary
  • 1184.14.36004 Boehringer Ingelheim Investigational Site
    Miskolc, Hungary
  • 1184.14.39001 Boehringer Ingelheim Investigational Site
    Pisa, Italy
  • 1184.14.37101 Boehringer Ingelheim Investigational Site
    Krāslava, Latvia
  • 1184.14.37103 Boehringer Ingelheim Investigational Site
    Kuldīga, Latvia
  • 1184.14.37102 Boehringer Ingelheim Investigational Site
    Talsi, Latvia
  • 1184.14.37003 Boehringer Ingelheim Investigational Site
    Klaipėda, Lithuania
  • 1184.14.31004 Boehringer Ingelheim Investigational Site
    Eindhoven, Netherlands
  • 1184.14.31003 Boehringer Ingelheim Investigational Site
    Heerlen, Netherlands
  • 1184.14.31002 Boehringer Ingelheim Investigational Site
    Nieuwegein, Netherlands
  • 1184.14.31001 Boehringer Ingelheim Investigational Site
    Veldhoven, Netherlands
  • 1184.14.42103 Boehringer Ingelheim Investigational Site
    Bardejov, Slovakia
  • 1184.14.82001 Boehringer Ingelheim Investigational Site
    Seoul, South Korea
  • 1184.14.82002 Boehringer Ingelheim Investigational Site
    Seoul, South Korea
  • 1184.14.82003 Boehringer Ingelheim Investigational Site
    Seoul, South Korea
  • 1184.14.46002 Boehringer Ingelheim Investigational Site
    Linköping, Sweden
  • 1184.14.46001 Boehringer Ingelheim Investigational Site
    Lund, Sweden
  • 1184.14.46003 Boehringer Ingelheim Investigational Site
    Sundsvall, Sweden
09

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2008 to primary completion in Nov 2008, 7 months.

Results were first posted in Oct 2026, 17 years 11 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2008
First posted
Apr 21, 2008
StartActual
Apr 15, 2008
Primary completionActual
Nov 21, 2008
CompletionActual
Nov 21, 2008
Results delay requested
Apr 30, 2014
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Sites
7 sites added, 7 sites removed
Show 7 added (2 Latvia, 1 Belgium, 1 Estonia, 1 Greece, 1 Hungary, 1 Lithuania)
  • 1184.14.32001 Boehringer Ingelheim Investigational Site · Brussels, Belgium
  • 1184.14.37202 Boehringer Ingelheim Investigational Site · Tallinn, Estonia
  • 1184.14.30004 Boehringer Ingelheim Investigational Site · Nafplion, Greece
  • 1184.14.36005 Boehringer Ingelheim Investigational Site · Komló, Hungary
  • 1184.14.37101 Boehringer Ingelheim Investigational Site · Krāslava, Latvia
  • 1184.14.37103 Boehringer Ingelheim Investigational Site · Kuldīga, Latvia
  • 1184.14.37003 Boehringer Ingelheim Investigational Site · Klaipėda, Lithuania
Show 7 removed
  • 1184.14.32001 Boehringer Ingelheim Investigational Site · Brussel, Belgium
  • 1184.14.37202 Boehringer Ingelheim Investigational Site · Tallin, Estonia
  • 1184.14.30004 Boehringer Ingelheim Investigational Site · Nafplio, Greece
  • 1184.14.36005 Boehringer Ingelheim Investigational Site · Komlo, Hungary
  • 1184.14.37101 Boehringer Ingelheim Investigational Site · Kraslava, Latvia
  • 1184.14.37103 Boehringer Ingelheim Investigational Site · Kuldiga, Latvia
  • 1184.14.37003 Boehringer Ingelheim Investigational Site · Klaipeda, Lithuania
Oct 29, 2026
Eligibility
3 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMain Inclusion criteria:
  • EditedDiagnosis of chronic obstructive pulmonary disease (COPD)
  • EditedPost-bronchodilator forced expiratory volume in one second (FEV1) <80% predicted and FEV1/forced vital capacity (FVC) <70% predicted
Exclusion criteria
  • EditedMain Exclusion criteria:
  • EditedUnstableAny unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year
  • EditedHospitalisation for cardiac failure induring the past year
Oct 29, 2026
Interventions
Changed Tiotropium/Salmeterol QD→FDC tiotropium / salmeterol. Removed Drug: Tiotropium/Salmeterol QD+ Salmeterol. Arms added: FDC tiotropium / salmeterol (T+S_PE)·tiotropium (Tio18GEL)·salmeterol (Salm25PE)·FDC tiotropium / salmeterol + salmeterol (T+S_PE / S25PE); arms removed: Tiotropium/Salmeterol quaque die (QD, once daily)·Tiotropium quaque die (QD, once daily)·Salmeterol bis in die (BID, twice daily)·Tiotropium/Salmeterol quaque die (QD, once daily)+ Salmeterol
Oct 29, 2026
Primary outcomes
3 edited, 6 added, 2 removed
What changed in the outcomes
  • EditedTrough forced expiratory volumeChange From Baseline in one secondTrough Forced Expiratory Volume in One Second (FEV1) responseat the End of the 12-week Treatment PeriodTime frame: 12 Weeks, 24 Weeks and 48 Weeks → At baseline and week 12
  • EditedMahler Transition Dyspnoea Index (TDI) focal scoreFocal Score at the End of the 12-week Treatment PeriodTime frame: 12 Weeks, 24 Weeks and 48 Weeks → At the end of week 12
  • EditedTime to first moderateFirst Moderate to severe Severe Chronic Obstructive Pulmonary Disease (COPD exacerbation) Exacerbation Within 48 WeeksTime frame: 12 Weeks, 24 Weeks and 48 Weeks → Up to 12 weeks
  • AddedChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment PeriodTime frame: At baseline and week 24
  • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment PeriodTime frame: At baseline and at week 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 24-week Treatment PeriodTime frame: At baseline and at week 24: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedMahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 24-week Treatment PeriodTime frame: At the end of week 24
  • AddedSt George Respiratory Questionnaire (SGRQ) Total Score at the End of the 24-week Treatment Period (Based Upon Pooled Data From 48-week Sister Studies 1184.14 and 1184.15)Time frame: At the end of week 24
  • AddedNumber of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 WeeksTime frame: Up to 12 weeks.
  • RemovedFEV1 area under the curve (AUC) 0-8h responseTime frame: 12 Weeks, 24 Weeks and 48 Weeks
  • RemovedSt George Respiratory Questionnaire (SGRQ) total scoreTime frame: 12 Weeks, 24 Weeks and 48 Weeks
Oct 29, 2026
Secondary outcomes
5 edited, 25 added, 26 more
What changed in the outcomes
  • EditedUseWeekly Mean Number Per Day of rescue medication (weekly mean numberPuffs of puffs of asAs-needed salbutamolSalbutamol/albuterol per day, daytime and night-timeAlbuterol Metered Dose Inhaler (MDI)Time frame: 24 hours → Weekly up to week 14: per day (24 hours period)
  • EditedWeekly mean numberMean Number of Chronic Obstructive Pulmonary Disease (COPD related night time awakenings)-Related Nighttime AwakeningsTime frame: 1 week → Per week, up to 14 weeks
  • EditedVital statusStatus of randomised patientsRandomised PatientsTime frame: 48 weeks → Up to 48 weeks.
  • EditedNumber of unscheduled health care provider visitsUnscheduled Health Care Provider Visits Within the 48-week Treatment PeriodTime frame: 48 weeks → Up to 12 weeks.
  • EditedNumber of daysDays in intensive care unitIntensive Care Unit Within the 48-week Treatment PeriodTime frame: 48 weeks → Up to 12 weeks.
  • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and at week 4: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and week 4
  • AddedChange From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48Time frame: At baseline and at week 4 and 12: within 3h after inhalation of the morning dose of randomised treatment.
  • AddedThe Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and at week 4 and 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedChange From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and week 4 and 12
  • AddedChange From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48Time frame: At baseline and at week 4 and 12: within 3 hours after inhalation of the morning dose of randomised treatment.
  • AddedForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
  • AddedWeekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
  • AddedWeekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)Time frame: At week 1 to 14, each evening between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
  • AddedPeak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48Time frame: At week 4 and 12: 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment.
  • AddedWeekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
  • AddedWeekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)Time frame: At week 1 to 14, each morning between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
  • AddedWeekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)Time frame: Weekly up to week 14: at daytime (from morning dose till evening dose of study medication)
  • AddedWeekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)Time frame: Weekly up to week 14: at nighttime (from evening dose till morning dose of study medication)
  • AddedMahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment PeriodTime frame: At week 4
  • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
  • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
  • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
  • AddedSt George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 WeeksTime frame: At week 4 and 12.
  • AddedSt George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 WeeksTime frame: At week 4 and 12.
  • …and 26 more, on the record history on ClinicalTrials.gov ↗
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    7 sites added, 7 sites removed
    Show 7 added (2 Latvia, 1 Belgium, 1 Estonia, 1 Greece, 1 Hungary, 1 Lithuania)
    • 1184.14.32001 Boehringer Ingelheim Investigational Site · Brussels, Belgium
    • 1184.14.37202 Boehringer Ingelheim Investigational Site · Tallinn, Estonia
    • 1184.14.30004 Boehringer Ingelheim Investigational Site · Nafplion, Greece
    • 1184.14.36005 Boehringer Ingelheim Investigational Site · Komló, Hungary
    • 1184.14.37101 Boehringer Ingelheim Investigational Site · Krāslava, Latvia
    • 1184.14.37103 Boehringer Ingelheim Investigational Site · Kuldīga, Latvia
    • 1184.14.37003 Boehringer Ingelheim Investigational Site · Klaipėda, Lithuania
    Show 7 removed
    • 1184.14.32001 Boehringer Ingelheim Investigational Site · Brussel, Belgium
    • 1184.14.37202 Boehringer Ingelheim Investigational Site · Tallin, Estonia
    • 1184.14.30004 Boehringer Ingelheim Investigational Site · Nafplio, Greece
    • 1184.14.36005 Boehringer Ingelheim Investigational Site · Komlo, Hungary
    • 1184.14.37101 Boehringer Ingelheim Investigational Site · Kraslava, Latvia
    • 1184.14.37103 Boehringer Ingelheim Investigational Site · Kuldiga, Latvia
    • 1184.14.37003 Boehringer Ingelheim Investigational Site · Klaipeda, Lithuania
    Eligibility 3 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMain Inclusion criteria:
    • EditedDiagnosis of chronic obstructive pulmonary disease (COPD)
    • EditedPost-bronchodilator forced expiratory volume in one second (FEV1) <80% predicted and FEV1/forced vital capacity (FVC) <70% predicted
    Exclusion criteria
    • EditedMain Exclusion criteria:
    • EditedUnstableAny unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year
    • EditedHospitalisation for cardiac failure induring the past year
    Primary outcomes 3 edited, 6 added, 2 removed
    What changed in the outcomes
    • EditedTrough forced expiratory volumeChange From Baseline in one secondTrough Forced Expiratory Volume in One Second (FEV1) responseat the End of the 12-week Treatment PeriodTime frame: 12 Weeks, 24 Weeks and 48 Weeks → At baseline and week 12
    • EditedMahler Transition Dyspnoea Index (TDI) focal scoreFocal Score at the End of the 12-week Treatment PeriodTime frame: 12 Weeks, 24 Weeks and 48 Weeks → At the end of week 12
    • EditedTime to first moderateFirst Moderate to severe Severe Chronic Obstructive Pulmonary Disease (COPD exacerbation) Exacerbation Within 48 WeeksTime frame: 12 Weeks, 24 Weeks and 48 Weeks → Up to 12 weeks
    • AddedChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment PeriodTime frame: At baseline and week 24
    • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 12-week Treatment PeriodTime frame: At baseline and at week 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response at the End of the 24-week Treatment PeriodTime frame: At baseline and at week 24: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedMahler Transition Dyspnoea Index (TDI) Focal Score at the End of the 24-week Treatment PeriodTime frame: At the end of week 24
    • AddedSt George Respiratory Questionnaire (SGRQ) Total Score at the End of the 24-week Treatment Period (Based Upon Pooled Data From 48-week Sister Studies 1184.14 and 1184.15)Time frame: At the end of week 24
    • AddedNumber of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Within 48 WeeksTime frame: Up to 12 weeks.
    • RemovedFEV1 area under the curve (AUC) 0-8h responseTime frame: 12 Weeks, 24 Weeks and 48 Weeks
    • RemovedSt George Respiratory Questionnaire (SGRQ) total scoreTime frame: 12 Weeks, 24 Weeks and 48 Weeks
    Secondary outcomes 5 edited, 25 added, 26 more
    What changed in the outcomes
    • EditedUseWeekly Mean Number Per Day of rescue medication (weekly mean numberPuffs of puffs of asAs-needed salbutamolSalbutamol/albuterol per day, daytime and night-timeAlbuterol Metered Dose Inhaler (MDI)Time frame: 24 hours → Weekly up to week 14: per day (24 hours period)
    • EditedWeekly mean numberMean Number of Chronic Obstructive Pulmonary Disease (COPD related night time awakenings)-Related Nighttime AwakeningsTime frame: 1 week → Per week, up to 14 weeks
    • EditedVital statusStatus of randomised patientsRandomised PatientsTime frame: 48 weeks → Up to 48 weeks.
    • EditedNumber of unscheduled health care provider visitsUnscheduled Health Care Provider Visits Within the 48-week Treatment PeriodTime frame: 48 weeks → Up to 12 weeks.
    • EditedNumber of daysDays in intensive care unitIntensive Care Unit Within the 48-week Treatment PeriodTime frame: 48 weeks → Up to 12 weeks.
    • AddedForced Expiratory Volume in One Second (FEV1) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and at week 4: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedChange From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) After 4, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and week 4
    • AddedChange From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) at Week 4, 12, 18, 24, 36 and 48Time frame: At baseline and at week 4 and 12: within 3h after inhalation of the morning dose of randomised treatment.
    • AddedThe Forced Vital Capacity (FVC) Area Under the Concentration-time Curve From 0 to 8h (AUC0-8h) Response After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and at week 4 and 12: 10 minutes (min) prior to inhalation, and 30min, 60min, 2hours (hrs), 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedChange From Baseline in Trough Forced Vital Capacity (FVC) After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At baseline and week 4 and 12
    • AddedChange From Baseline in Peak Forced Vital Capacity (FVC) at Week 4, 12, 18, 24, 36 and 48Time frame: At baseline and at week 4 and 12: within 3 hours after inhalation of the morning dose of randomised treatment.
    • AddedForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedForced Expiratory Volume in One Second (FEV1) at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedForced Vital Capacity (FVC) at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 4Time frame: At week 4, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedPeak Expiratory Flow (PEF) Rate at Clinic Visits at the Individual Times on Week 12Time frame: At week 12, at 10 min prior and 0 hours (hrs), 30 minutes (min), 1hrs, 2hrs, 3hrs, 4hrs, 6hrs and 8hrs after inhalation of the morning drug dose.
    • AddedWeekly Mean Morning Pre-dose Peak Expiratory Flows (PEFs)Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
    • AddedWeekly Mean Evening Pre-dose Peak Expiratory Flows (PEFs)Time frame: At week 1 to 14, each evening between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
    • AddedPeak Expiratory Flow (PEF) Determined by Spirometry at Week 4, 12, 18, 24, 36 and 48Time frame: At week 4 and 12: 10 minutes prior to the first dose of study medication, and at 30, 60 minutes, 2, 3, 4, 6 and 8 hours after inhalation of the first dose of randomised treatment.
    • AddedWeekly Mean Morning Pre-dose Forced Expiratory Volume in One Second (FEV1)Time frame: At week 1 to 14, each morning between 7 a.m. and 10 a.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
    • AddedWeekly Mean Evening Pre-dose Forced Expiratory Volume in One Second (FEV1)Time frame: At week 1 to 14, each morning between 7 p.m. and 10 p.m. (± 30 minutes (min)) at -10 min (± 3 min) prior to the administration of the study medication.
    • AddedWeekly Mean Number at Daytime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)Time frame: Weekly up to week 14: at daytime (from morning dose till evening dose of study medication)
    • AddedWeekly Mean Number at Nighttime of Puffs of As-needed Salbutamol/Albuterol Metered Dose Inhaler (MDI)Time frame: Weekly up to week 14: at nighttime (from evening dose till morning dose of study medication)
    • AddedMahler Transition Dyspnoea Index (TDI) Focal Score Collected After 4, 36 and 48 Weeks Treatment PeriodTime frame: At week 4
    • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Functional Impairment Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
    • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Task Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
    • AddedMahler Transition Dyspnoea Index (TDI) Domain Score - Magnitude of Effort Collected After 4, 12, 24, 36 and 48 Weeks Treatment PeriodTime frame: At the end of week 4 and 12.
    • AddedSt George Respiratory Questionnaire (SGRQ) Total Score Collected at 4, 12, 36 and 48 WeeksTime frame: At week 4 and 12.
    • AddedSt George Respiratory Questionnaire (SGRQ) Impact Domain Score Collected at 4, 12, 36 and 48 WeeksTime frame: At week 4 and 12.
    • …and 26 more, on the record history on ClinicalTrials.gov ↗
    Interventions Changed Tiotropium/Salmeterol QD→FDC tiotropium / salmeterol. Removed Drug: Tiotropium/Salmeterol QD+ Salmeterol. Arms added: FDC tiotropium / salmeterol (T+S_PE)·tiotropium (Tio18GEL)·salmeterol (Salm25PE)·FDC tiotropium / salmeterol + salmeterol (T+S_PE / S25PE); arms removed: Tiotropium/Salmeterol quaque die (QD, once daily)·Tiotropium quaque die (QD, once daily)·Salmeterol bis in die (BID, twice daily)·Tiotropium/Salmeterol quaque die (QD, once daily)+ Salmeterol
    + 5 other changes: verification date, design details, oversight details, registry notes and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00662740
Responsible party
Sponsor
First posted
Apr 21, 2008
Start date
Apr 15, 2008
Primary completion
Nov 21, 2008
Completion
Nov 21, 2008
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion